pH responsive Fe3O4@GT/PVA nanocomposite for drug release of hydroxychloroquine sulfate (HCQ) [post]

Ali Zandi, Hossein Abbastabar Ahangar, Ali Saffar
2022 unpublished
Recent studies have shown the potential of hydroxychloroquine (HCQ) as a pharmaceutical agent to the treatment of a variety of cancers such as lung, melanoma, breast, pancreatic, and colon cancers. HCQ has been proposed to cure viral diseases such as Covid-19 disease. In this study, Fe3O4@PVA/GT nanocomposite has been synthesized for controlling HCQ release at pH 7.4 and 3.4 in different temperature (37 0C and 40 0C). Taguchi method (L9) with 3 levels and 3 factors was used to optimize the
more » ... ence of the ratio of PVA (polyvinyl alcohol) to GT (gum tragacanth), Fe3O4 weight percent, and the amount of crosslinking agent (citric acid) on the swelling and releasing rate. The influence of different factors were studied on the swelling and releasing rate such as the ratio of PVA (polyvinyl alcohol) to GT (gum tragacanth), the amount of Fe3O4 and the amount of crosslinking agent (citric acid), by the Taguchi method with 3 factors at 3 levels. The obtained results showed that increasing the amount of Fe3O4 decreased the drug release rate. Increasing the amount of GT to PVA increased the sensitivity of the nanocomposite to pH. So that in neutral pH had the lowest drug release and in acidic pH had the highest drug release. After 18 hours, sample with PVA / GT ratio 0.85:0.15 (wt/wt), CA 3% (wt) and 2% (wt) Fe3O4 had the cumulative drug release 71.57 % and 52.37% in pH 3.4 and 7.4 at 40 0C, respectively.
doi:10.21203/rs.3.rs-1799339/v1 fatcat:pzcjt2gtynacposc36pugu6cjy